NEW YORK - Tiziana Life Sciences Ltd (NASDAQ:TLSA), a biotech company specializing in immunomodulation therapies, reported significant findings from its ongoing research into the treatment of non-active secondary progressive multiple sclerosis (na-SPMS). Last week, at the American Academy of Neurology annual meeting, the company presented data indicating that their intranasal foralumab therapy reduced brain inflammation in na-SPMS patients.
The study utilized [F18]PBR06-PET imaging to measure microglial activation, a marker of brain inflammation, before and after three months of treatment. Results showed a median reduction of 36% in White Matter Z-scores, a statistical measure assessing brain integrity. Improvements were observed in 5 out of 6 patients, with reductions ranging from 28% to 48%.
These findings, published in the peer-reviewed journal Clinical Nuclear Medicine, build on previous data showing that intranasal foralumab attenuated microglial activation and was associated with clinical symptom improvement or stability in na-SPMS patients.
The company is currently conducting a double-blind, placebo-controlled, dose-ranging study (NCT06292923) with [F-18]PBR06-PET as a primary endpoint, complemented by clinical measures of disability and fatigue. This research could potentially lead to new treatment avenues for neuroinflammatory and neurodegenerative diseases.
Foralumab, the only fully human anti-CD3 monoclonal antibody, modulates T cell function and inflammation. The Phase 2 trial for the intranasal administration of foralumab began patient screening in November 2023.
Tiziana Life Sciences aims to leverage its drug delivery technologies to improve therapy efficacy and patient tolerability over traditional intravenous methods. The company's patented technology and pending applications seek to expand the pipeline of immunotherapy treatments.
The information in this article is based on a press release statement.
InvestingPro Insights
Tiziana Life Sciences Ltd (NASDAQ:TLSA), while presenting promising research outcomes, continues to navigate the financial complexities inherent in the biotech industry. An analysis of real-time data from InvestingPro reveals some key financial metrics that can provide a broader perspective to investors interested in the company's market performance.
With a market capitalization of approximately $79.25 million, Tiziana Life Sciences is a smaller player in the biotech space, which can often mean higher volatility in stock performance. This is reflected in the company's significant price total return of 23.45% over the last week and an impressive 74.42% over the past month. These figures suggest a strong recent uptrend in the stock's value, potentially indicating investor optimism following the latest research announcements.
Despite these positive returns, the company's financial health shows areas of concern. The Price / Book ratio stands at 6.34 as of the last twelve months ending Q2 2023, which is high compared to industry averages and may suggest that the stock is trading at a premium. Additionally, the company's negative EBITDA growth rate of -26.06% over the same period highlights challenges in earnings before interest, taxes, depreciation, and amortization.
InvestingPro Tips for Tiziana Life Sciences underscore the company's current lack of profitability, with analysts not anticipating the company to be profitable this year. Moreover, the stock is considered to be in overbought territory according to the Relative Strength Index (RSI), which could signal a potential pullback in the near future.
For investors seeking a deeper dive into Tiziana Life Sciences' financial performance and future outlook, there are additional InvestingPro Tips available. These tips can provide valuable insights to inform investment decisions. To discover the full range of expert analysis, visit https://www.investing.com/pro/TLSA and use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription. Currently, there are 11 more InvestingPro Tips available for Tiziana Life Sciences that can further enrich your investment strategy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.